irbesartan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 1481 138402-11-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • irbesartan
  • aprovel
  • irbesartan hydrochloride
  • karvea
  • ifirmasta
  • irbesartan HCl
A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
  • Molecular weight: 428.54
  • Formula: C25H28N6O
  • CLOGP: 6.04
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 87.13
  • ALOGS: -4.70
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.08 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.94 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 30, 1997 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 534.85 10.19 954 54932 252914 53040266
Hyponatraemia 456.09 10.19 565 55321 108042 53185138
Neurologic neglect syndrome 238.63 10.19 76 55810 1099 53292081
Carotid artery thrombosis 235.09 10.19 76 55810 1156 53292024
Personality disorder 199.76 10.19 94 55792 4037 53289143
Adjustment disorder 198.35 10.19 75 55811 1848 53291332
Hemiplegia 171.36 10.19 105 55781 7695 53285485
Hyperkalaemia 161.41 10.19 239 55647 54017 53239163
Lactic acidosis 148.38 10.19 189 55697 37064 53256116
Affect lability 132.75 10.19 96 55790 9279 53283901
Rheumatoid arthritis 125.83 10.19 88 55798 314443 52978737
Fall 118.16 10.19 709 55177 357731 52935449
Sensory loss 116.64 10.19 83 55803 7822 53285358
Drug ineffective 116.24 10.19 453 55433 816792 52476388
Motor dysfunction 106.13 10.19 80 55806 8238 53284942
Pain 100.53 10.19 301 55585 588097 52705083
Aphasia 99.39 10.19 141 55745 30637 53262543
Maternal exposure during pregnancy 89.48 10.19 26 55860 155613 53137567
Eating disorder 89.14 10.19 97 55789 16100 53277080
Treatment failure 88.96 10.19 14 55872 128389 53164791
Renal failure 88.32 10.19 299 55587 118153 53175027
Coordination abnormal 86.56 10.19 83 55803 11868 53281312
Drug interaction 85.42 10.19 454 55432 218875 53074305
Hypoglycaemia 81.95 10.19 187 55699 58826 53234354
Hypotension 81.28 10.19 499 55387 253577 53039603
Hemiparesis 80.87 10.19 106 55780 21369 53271811
Muscle spasticity 79.85 10.19 96 55790 17742 53275438
Therapeutic product effect decreased 75.97 10.19 19 55867 125636 53167544
Contraindicated product administered 75.52 10.19 24 55862 135605 53157575
Sinus bradycardia 74.41 10.19 84 55802 14517 53278663
Glossodynia 74.03 10.19 9 55877 100282 53192898
Systemic lupus erythematosus 73.84 10.19 20 55866 125394 53167786
Drug hypersensitivity 70.94 10.19 105 55781 265137 53028043
Blood pressure increased 70.62 10.19 313 55573 140166 53153014
Hand deformity 69.56 10.19 5 55881 84844 53208336
Hypertension 64.19 10.19 430 55456 225001 53068179
Synovitis 63.90 10.19 17 55869 107876 53185304
Cerebrovascular accident 61.14 10.19 245 55641 104929 53188251
Bradycardia 60.74 10.19 188 55698 70868 53222312
Hypertensive crisis 58.37 10.19 74 55812 14432 53278748
Blood pressure systolic increased 57.41 10.19 119 55767 35058 53258122
Off label use 55.74 10.19 280 55606 471932 52821248
Hepatocellular injury 55.61 10.19 107 55779 29879 53263301
Ischaemic stroke 54.53 10.19 80 55806 17913 53275267
Atrial fibrillation 54.01 10.19 246 55640 111406 53181774
Dysarthria 53.50 10.19 126 55760 40442 53252738
Pemphigoid 52.92 10.19 48 55838 6396 53286784
Confusional state 52.60 10.19 366 55520 193855 53099325
Death 48.56 10.19 201 55685 357031 52936149
Syncope 48.52 10.19 239 55647 111754 53181426
Arthropathy 47.30 10.19 47 55839 141406 53151774
Rhabdomyolysis 47 10.19 126 55760 43797 53249383
Hypokalaemia 46.93 10.19 213 55673 96304 53196876
Inappropriate antidiuretic hormone secretion 46.07 10.19 67 55819 14884 53278296
Swelling 46.03 10.19 81 55805 191024 53102156
Vertigo 45.73 10.19 146 55740 55935 53237245
Alopecia 44.33 10.19 114 55772 234469 53058711
Exposure during pregnancy 43.48 10.19 40 55846 124820 53168360
Asthenia 43.46 10.19 550 55336 343040 52950140
Cholestasis 43.27 10.19 94 55792 28601 53264579
Dehydration 42.47 10.19 312 55574 168098 53125082
Joint swelling 39.90 10.19 120 55766 234518 53058662
Atrioventricular block first degree 39.24 10.19 41 55845 6494 53286686
Shock haemorrhagic 38.79 10.19 48 55838 9135 53284045
Product dose omission issue 37.06 10.19 92 55794 191528 53101652
Pericarditis 36.55 10.19 11 55875 64395 53228785
Infection 36.26 10.19 79 55807 172126 53121054
Oedema peripheral 36.22 10.19 304 55582 170483 53122697
Abdominal discomfort 36.20 10.19 115 55771 220947 53072233
Therapeutic product effect incomplete 36.19 10.19 26 55860 91758 53201422
Fear of eating 35.79 10.19 14 55872 379 53292801
Arteriovenous fistula occlusion 35.79 10.19 14 55872 379 53292801
Atrioventricular block complete 35.64 10.19 43 55843 7972 53285208
Blue toe syndrome 34.79 10.19 14 55872 409 53292771
Completed suicide 34.71 10.19 57 55829 138144 53155036
Drug intolerance 34.28 10.19 106 55780 205387 53087793
Product use issue 32.84 10.19 60 55826 139524 53153656
Angioedema 31.13 10.19 106 55780 41970 53251210
Muscular weakness 30.72 10.19 196 55690 100796 53192384
Hepatic cytolysis 29.80 10.19 39 55847 7846 53285334
Rash 29.52 10.19 312 55574 445879 52847301
Tubulointerstitial nephritis 29.51 10.19 58 55828 16446 53276734
Malaise 29.08 10.19 531 55355 357086 52936094
Renal impairment 28.05 10.19 166 55720 83152 53210028
Dysphagia 27.68 10.19 167 55719 84230 53208950
Prothrombin time ratio decreased 27.01 10.19 12 55874 450 53292730
Neurofibrosarcoma 26.91 10.19 9 55877 153 53293027
Blood potassium increased 26.39 10.19 58 55828 17783 53275397
Anuria 26.33 10.19 47 55839 12393 53280787
Hypersensitivity 25.87 10.19 123 55763 210542 53082638
Vascular purpura 25.68 10.19 17 55869 1424 53291756
Blood pressure fluctuation 25.05 10.19 88 55798 35382 53257798
Haematoma 24.80 10.19 85 55801 33759 53259421
International normalised ratio increased 24.40 10.19 107 55779 47654 53245526
Psoriatic arthropathy 24.31 10.19 10 55876 48180 53245000
Sinus arrest 24.11 10.19 18 55868 1826 53291354
Acidosis 24.06 10.19 43 55843 11349 53281831
Febrile neutropenia 23.89 10.19 46 55840 104890 53188290
Blood creatinine increased 23.66 10.19 158 55728 82504 53210676
Meningorrhagia 23.60 10.19 8 55878 142 53293038
Intestinal angioedema 23.31 10.19 12 55874 627 53292553
Hypergammaglobulinaemia 23.16 10.19 11 55875 482 53292698
Haemangioma congenital 22.97 10.19 11 55875 491 53292689
Blood pressure inadequately controlled 22.91 10.19 27 55859 4884 53288296
Anal polyp 22.62 10.19 6 55880 43 53293137
Blood sodium decreased 22.43 10.19 64 55822 23052 53270128
Injection site reaction 22.20 10.19 13 55873 51153 53242027
Heart rate decreased 22.19 10.19 87 55799 36860 53256320
Injection site erythema 22.19 10.19 29 55857 77220 53215960
Sinusitis 22.13 10.19 96 55790 168468 53124712
Toxicity to various agents 22.12 10.19 137 55749 219461 53073719
Prevertebral soft tissue swelling of cervical space 22.04 10.19 6 55880 48 53293132
Interstitial lung disease 21.83 10.19 120 55766 58502 53234678
Discomfort 21.60 10.19 42 55844 95430 53197750
Diabetic metabolic decompensation 21.53 10.19 16 55870 1612 53291568
Cutaneous vasculitis 21.42 10.19 25 55861 4476 53288704
Torsade de pointes 21.22 10.19 44 55842 12961 53280219
Renin decreased 21.21 10.19 7 55879 114 53293066
Hypochloraemia 21.10 10.19 17 55869 1929 53291251
Eosinophilia 20.64 10.19 59 55827 21276 53271904
Primary hyperaldosteronism 20.33 10.19 6 55880 66 53293114
Botryomycosis 20.22 10.19 5 55881 26 53293154
Dermatitis bullous 20.12 10.19 33 55853 8130 53285050
Coronary artery disease 19.49 10.19 78 55808 33359 53259821
Loss of consciousness 19.46 10.19 194 55692 114018 53179162
Injection site pain 19.24 10.19 58 55828 113333 53179847
Haemodialysis 19.23 10.19 35 55851 9369 53283811
Milk-alkali syndrome 19.12 10.19 11 55875 717 53292463
Fatigue 19.04 10.19 602 55284 729904 52563276
Vulvar basal cell carcinoma 18.95 10.19 5 55881 35 53293145
Blood aldosterone increased 18.27 10.19 7 55879 179 53293001
Duodenal ulcer perforation 18.24 10.19 7 55879 35176 53258004
Dizziness 18.05 10.19 514 55372 371745 52921435
Electrolyte imbalance 18.05 10.19 52 55834 18832 53274348
Hyperlactacidaemia 18.00 10.19 18 55868 2707 53290473
Upper respiratory tract infection 17.81 10.19 28 55858 69069 53224111
Histoplasmosis 17.72 10.19 15 55871 1823 53291357
Irritable bowel syndrome 17.67 10.19 12 55874 43620 53249560
Wound 17.65 10.19 44 55842 91513 53201667
Abortion spontaneous 17.37 10.19 14 55872 46621 53246559
Hepatitis 17.36 10.19 76 55810 33818 53259362
Congenital musculoskeletal anomaly 17.27 10.19 9 55877 482 53292698
Product use in unapproved indication 17.27 10.19 60 55826 112229 53180951
Sebaceous gland infection 17.22 10.19 6 55880 116 53293064
Cardiac failure 17.22 10.19 151 55735 85693 53207487
Renal pain 17.12 10.19 26 55860 6001 53287179
Reversible cerebral vasoconstriction syndrome 17.03 10.19 16 55870 2229 53290951
Left atrial dilatation 16.98 10.19 15 55871 1930 53291250
Blood pressure diastolic decreased 16.77 10.19 47 55839 16756 53276424
Brucellosis 16.63 10.19 5 55881 59 53293121
Myocardial infarction 16.56 10.19 168 55718 99186 53193994
Sepsis 16.53 10.19 88 55798 146341 53146839
Product substitution issue 16.45 10.19 45 55841 15821 53277359
Arthralgia 16.34 10.19 344 55542 439439 52853741
Incision site haemorrhage 16.27 10.19 9 55877 544 53292636
Orthostatic hypotension 16.23 10.19 68 55818 29685 53263495
Cardiac ventricular thrombosis 16.18 10.19 9 55877 550 53292630
Impaired healing 15.63 10.19 27 55859 64178 53229002
Adverse drug reaction 15.53 10.19 20 55866 53605 53239575
Hospitalisation 15.41 10.19 32 55854 70980 53222200
Emphysematous cystitis 15.39 10.19 6 55880 161 53293019
Body temperature decreased 15.14 10.19 45 55841 16582 53276598
Depression 15.09 10.19 121 55765 182931 53110249
Electrocardiogram QT prolonged 15.06 10.19 106 55780 56297 53236883
Intentional self-injury 14.93 10.19 4 55882 25280 53267900
Pulmonary artery atresia 14.92 10.19 4 55882 30 53293150
Jaundice 14.79 10.19 67 55819 30246 53262934
Oliguria 14.77 10.19 31 55855 9207 53283973
Enterococcal sepsis 14.74 10.19 12 55874 1382 53291798
Intra-abdominal haematoma 14.72 10.19 13 55873 1672 53291508
Device related infection 14.65 10.19 3 55883 22783 53270397
Shock 14.31 10.19 55 55831 23084 53270096
Sinus node dysfunction 14.10 10.19 20 55866 4341 53288839
Electrocardiogram PR prolongation 14.08 10.19 9 55877 710 53292470
Disease progression 14.02 10.19 57 55829 101863 53191317
Wrong patient received product 13.95 10.19 14 55872 2114 53291066
Retching 13.93 10.19 39 55847 13894 53279286
Premature delivery 13.85 10.19 5 55881 26099 53267081
Injection site pruritus 13.68 10.19 14 55872 41575 53251605
Necrotising myositis 13.68 10.19 7 55879 361 53292819
Disorientation 13.61 10.19 79 55807 39280 53253900
Hypochromic anaemia 13.45 10.19 13 55873 1876 53291304
Device dislocation 13.44 10.19 4 55882 23593 53269587
Respiratory acidosis 13.35 10.19 24 55862 6364 53286816
Malignant neoplasm progression 13.31 10.19 35 55851 71506 53221674
Injection site swelling 13.30 10.19 15 55871 42613 53250567
Pulmonary pain 13.09 10.19 14 55872 2278 53290902
Skin sensitisation 13.04 10.19 9 55877 807 53292373
Pneumonia 13.00 10.19 326 55560 406843 52886337
Parotid gland enlargement 12.95 10.19 9 55877 816 53292364
Musculoskeletal stiffness 12.91 10.19 76 55810 123292 53169888
Drug ineffective for unapproved indication 12.77 10.19 3 55883 20717 53272463
Pure white cell aplasia 12.74 10.19 4 55882 55 53293125
Tendon injury 12.72 10.19 12 55874 1680 53291500
Multiple sclerosis relapse 12.71 10.19 17 55869 44836 53248344
Fundoscopy abnormal 12.58 10.19 3 55883 13 53293167
Transient ischaemic attack 12.55 10.19 72 55814 35653 53257527
Anaphylactic reaction 12.43 10.19 104 55782 58222 53234958
Ascites 12.38 10.19 14 55872 39721 53253459
Migraine 12.34 10.19 43 55843 80374 53212806
Oropharyngeal swelling 12.28 10.19 9 55877 887 53292293
Acute coronary syndrome 12.27 10.19 31 55855 10393 53282787
Cerebral haemorrhage 12.26 10.19 63 55823 29933 53263247
Subacute kidney injury 12.23 10.19 3 55883 15 53293165
Rash morbilliform 12.12 10.19 16 55870 3247 53289933
Drug resistance 12.09 10.19 3 55883 19959 53273221
Anaemia 12.02 10.19 377 55509 276341 53016839
Injection site bruising 12.02 10.19 13 55873 37633 53255547
Haematoma muscle 11.96 10.19 8 55878 682 53292498
Impaired work ability 11.77 10.19 37 55849 14053 53279127
Peripheral swelling 11.68 10.19 149 55737 205959 53087221
Blood immunoglobulin E increased 11.53 10.19 13 55873 2242 53290938
Bronchopulmonary aspergillosis allergic 11.49 10.19 10 55876 1262 53291918
Renal tubular necrosis 11.45 10.19 32 55854 11387 53281793
Fibrous histiocytoma 11.44 10.19 7 55879 511 53292669
Condition aggravated 11.43 10.19 231 55655 296903 52996277
Physical assault 11.42 10.19 9 55877 989 53292191
Optic nerve infarction 11.37 10.19 3 55883 21 53293159
Localised oedema 11.16 10.19 20 55866 5289 53287891
Respiratory tract infection 11.14 10.19 11 55875 33213 53259967
Stomatitis 11.07 10.19 59 55827 98099 53195081
Oral lichen planus 11.06 10.19 7 55879 543 53292637
Subacute cutaneous lupus erythematosus 11.02 10.19 13 55873 2355 53290825
Blood pressure decreased 10.97 10.19 106 55780 61763 53231417
Ear pain 10.93 10.19 9 55877 29664 53263516
Helicobacter infection 10.88 10.19 15 55871 39054 53254126
Contraindicated product prescribed 10.85 10.19 8 55878 796 53292384
Hepatorenal syndrome 10.82 10.19 12 55874 2033 53291147
Drug abuse 10.77 10.19 34 55852 65492 53227688
C-reactive protein abnormal 10.63 10.19 7 55879 25863 53267317
Toxic skin eruption 10.51 10.19 34 55852 13105 53280075
White blood cell analysis abnormal 10.43 10.19 3 55883 30 53293150
Insulinoma 10.38 10.19 4 55882 104 53293076

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 295.96 10.83 916 39499 292552 32180559
Lactic acidosis 120.85 10.83 177 40238 33359 32439752
Death 114.07 10.83 188 40227 382329 32090782
Hyponatraemia 97.22 10.83 256 40159 74257 32398854
Hyperkalaemia 96.52 10.83 245 40170 69505 32403606
Oesophageal pain 59.73 10.83 26 40389 778 32472333
Anorectal discomfort 59.39 10.83 34 40381 1846 32471265
Hypoglycaemia 59.20 10.83 175 40240 54207 32418904
Hypotension 58.16 10.83 463 39952 215647 32257464
Drug abuse 56.41 10.83 15 40400 80228 32392883
Off label use 55.70 10.83 195 40220 306125 32166986
Bradycardia 52.78 10.83 202 40213 71360 32401751
Completed suicide 48.97 10.83 27 40388 92490 32380621
Eosinophilia 48.13 10.83 100 40315 24858 32448253
Seronegative arthritis 45.43 10.83 23 40392 974 32472137
Blood pressure increased 45.22 10.83 207 40208 79147 32393964
Fractured coccyx 45.17 10.83 14 40401 153 32472958
Syncope 44.09 10.83 225 40190 89899 32383212
Presyncope 41.49 10.83 76 40339 17225 32455886
Febrile neutropenia 41.09 10.83 53 40362 119513 32353598
Blood pressure systolic increased 39.94 10.83 75 40340 17321 32455790
Foetal exposure during pregnancy 39.85 10.83 3 40412 41298 32431813
Drug ineffective 39.57 10.83 297 40118 383180 32089931
N-terminal prohormone brain natriuretic peptide abnormal 37.83 10.83 13 40402 201 32472910
Failure to suspend medication 35.88 10.83 14 40401 315 32472796
Blood thyroid stimulating hormone abnormal 35.40 10.83 13 40402 246 32472865
Pneumonia 34.81 10.83 279 40136 354973 32118138
Treatment failure 34.71 10.83 4 40411 39159 32433952
Pulmonary arterial pressure abnormal 34.26 10.83 12 40403 197 32472914
Lipoma 33.79 10.83 22 40393 1506 32471605
Electrocardiogram QRS complex abnormal 32.50 10.83 13 40402 313 32472798
Eczema 32.43 10.83 63 40352 14917 32458194
Brain natriuretic peptide abnormal 31.28 10.83 13 40402 346 32472765
Oxygen saturation increased 31.22 10.83 12 40403 259 32472852
Agranulocytosis 30.91 10.83 81 40334 23396 32449715
Rhabdomyolysis 30.85 10.83 165 40250 67100 32406011
Disease progression 30.35 10.83 38 40377 86824 32386287
Blood creatinine increased 30.31 10.83 214 40201 95918 32377193
Fall 29.58 10.83 373 40042 195828 32277283
Lung diffusion test decreased 28.95 10.83 15 40400 667 32472444
Congenital diaphragmatic anomaly 28.61 10.83 7 40408 28 32473083
Tongue abscess 28.46 10.83 5 40410 0 32473111
Renal failure 28.21 10.83 273 40142 134205 32338906
Arrhythmia 27.96 10.83 102 40313 35201 32437910
Dysgeusia 27.61 10.83 82 40333 25449 32447662
Carotid arteriosclerosis 27.61 10.83 17 40398 1056 32472055
Plasma cell myeloma 27.44 10.83 19 40396 57595 32415516
Gastrointestinal motility disorder 27.41 10.83 23 40392 2324 32470787
Hypoparathyroidism 27.38 10.83 13 40402 478 32472633
Mycobacterium test positive 27.35 10.83 12 40403 366 32472745
Drug interaction 26.85 10.83 400 40015 217785 32255326
Pemphigoid 26.78 10.83 42 40373 8394 32464717
Hypovolaemia 26.54 10.83 43 40372 8834 32464277
Vomiting projectile 25.64 10.83 14 40401 693 32472418
Left ventricular dilatation 25.56 10.83 14 40401 697 32472414
Cerebrovascular accident 24.82 10.83 188 40227 86132 32386979
Vestibular neuronitis 24.43 10.83 9 40406 172 32472939
Product dose omission issue 23.88 10.83 58 40357 102517 32370594
Pancreatitis acute 23.37 10.83 81 40334 27254 32445857
Antiphospholipid antibodies positive 22.89 10.83 10 40405 302 32472809
Wrong patient received product 22.51 10.83 21 40394 2441 32470670
Sepsis 22.03 10.83 112 40303 158722 32314389
Shock 21.98 10.83 73 40342 24041 32449070
Tachyarrhythmia 21.92 10.83 24 40391 3375 32469736
Anuria 21.56 10.83 44 40371 10793 32462318
Left atrial dilatation 21.16 10.83 18 40397 1854 32471257
Ear discomfort 21.01 10.83 20 40395 2384 32470727
Rash maculo-papular 20.55 10.83 79 40336 27943 32445168
Cholestasis 20.47 10.83 77 40338 26956 32446155
Blood creatine phosphokinase increased 20.47 10.83 111 40304 45365 32427746
Toxicity to various agents 20.17 10.83 134 40281 177907 32295204
Preternatural anus 20.09 10.83 7 40408 113 32472998
Acute pulmonary oedema 19.83 10.83 35 40380 7706 32465405
Mucosal dryness 19.63 10.83 14 40401 1113 32471998
Hypertension 19.61 10.83 250 40165 131500 32341611
Malignant neoplasm progression 19.38 10.83 43 40372 78453 32394658
Neutrophil count decreased 19.37 10.83 18 40397 47121 32425990
White blood cell count decreased 19.36 10.83 54 40361 91144 32381967
Procedural failure 19.24 10.83 6 40409 67 32473044
Mental status changes 19.12 10.83 12 40403 38325 32434786
Myopathy 19.06 10.83 43 40372 11298 32461813
Renal haemorrhage 19.01 10.83 15 40400 1390 32471721
Product use in unapproved indication 18.99 10.83 51 40364 87153 32385958
Supraventricular extrasystoles 18.92 10.83 22 40393 3303 32469808
SARS-CoV-2 sepsis 18.89 10.83 7 40408 136 32472975
Dyslipidaemia 18.78 10.83 32 40383 6851 32466260
Platelet count decreased 18.75 10.83 76 40339 114515 32358596
Morganella infection 18.69 10.83 10 40405 475 32472636
Diabetes mellitus inadequate control 18.63 10.83 48 40367 13720 32459391
Hyperlactacidaemia 18.61 10.83 21 40394 3053 32470058
Cerebral haematoma 18.20 10.83 26 40389 4785 32468326
Tenoplasty 18.06 10.83 4 40411 9 32473102
Melaena 17.95 10.83 88 40327 34577 32438534
Muscle strain 17.92 10.83 23 40392 3822 32469289
Lividity 17.92 10.83 7 40408 158 32472953
Pseudoporphyria 17.62 10.83 8 40407 265 32472846
Carcinoma in situ of skin 17.57 10.83 6 40409 91 32473020
Hospitalisation 17.54 10.83 21 40394 48950 32424161
Pruritus 17.40 10.83 240 40175 128462 32344649
Toxic skin eruption 17.30 10.83 42 40373 11572 32461539
Goitre 17.27 10.83 15 40400 1589 32471522
Nephrectomy 17.18 10.83 11 40404 732 32472379
Metabolic acidosis 16.76 10.83 97 40318 40602 32432509
Therapeutic product effect incomplete 16.73 10.83 16 40399 41325 32431786
Renal impairment 16.54 10.83 181 40234 91791 32381320
Dizziness 16.42 10.83 358 40057 209260 32263851
Atrial thrombosis 16.37 10.83 16 40399 1971 32471140
Precancerous skin lesion 16.36 10.83 10 40405 613 32472498
Conduction disorder 16.35 10.83 16 40399 1974 32471137
Lung disorder 16.29 10.83 84 40331 33670 32439441
Superficial spreading melanoma stage I 16.15 10.83 4 40411 17 32473094
Neoplasm prostate 16.10 10.83 7 40408 209 32472902
Myalgia 16.08 10.83 163 40252 81067 32392044
Haematocrit increased 16.05 10.83 15 40400 1748 32471363
Echinococciasis 15.97 10.83 4 40411 18 32473093
Rectal haemorrhage 15.94 10.83 90 40325 37333 32435778
Cardiac ablation 15.91 10.83 10 40405 644 32472467
Enterocutaneous fistula 15.90 10.83 11 40404 833 32472278
Sneezing 15.64 10.83 24 40391 4707 32468404
Enterochromaffin cell hyperplasia 15.46 10.83 4 40411 21 32473090
Haemochromatosis 15.42 10.83 12 40403 1089 32472022
Drug dependence 15.38 10.83 5 40410 23479 32449632
Periorbital haematoma 15.25 10.83 8 40407 365 32472746
Dermatitis exfoliative 15.17 10.83 31 40384 7613 32465498
Musculoskeletal discomfort 15.09 10.83 29 40386 6811 32466300
Bronchial haemorrhage 14.99 10.83 10 40405 713 32472398
Vascular purpura 14.86 10.83 14 40401 1648 32471463
Drug resistance 14.84 10.83 5 40410 22960 32450151
Eosinophilic pleural effusion 14.83 10.83 7 40408 254 32472857
Blood lactic acid 14.76 10.83 8 40407 390 32472721
Product substitution issue 14.76 10.83 37 40378 10399 32462712
Oedema peripheral 14.71 10.83 211 40204 113880 32359231
Bundle branch block left 14.63 10.83 26 40389 5753 32467358
Drug hypersensitivity 14.46 10.83 45 40370 73355 32399756
Hepatocellular injury 14.37 10.83 66 40349 25252 32447859
Shock haemorrhagic 14.29 10.83 37 40378 10608 32462503
Asthenia 14.27 10.83 389 40026 235555 32237556
Respiratory failure 14.05 10.83 77 40338 107105 32366006
Rheumatoid arthritis 14.02 10.83 21 40394 44523 32428588
Inflammation 14.01 10.83 64 40351 24429 32448682
Sedation 13.92 10.83 3 40412 18523 32454588
Inflammatory marker increased 13.88 10.83 20 40395 3709 32469402
Blood pressure inadequately controlled 13.83 10.83 17 40398 2705 32470406
Blood creatine increased 13.78 10.83 23 40392 4842 32468269
Granuloma 13.76 10.83 17 40398 2718 32470393
Appetite disorder 13.75 10.83 15 40400 2100 32471011
Blood osmolarity decreased 13.64 10.83 9 40406 630 32472481
Interstitial lung disease 13.62 10.83 132 40283 64869 32408242
Hepatitis 13.62 10.83 62 40353 23631 32449480
Atrial fibrillation 13.55 10.83 212 40203 116492 32356619
Renal cyst 13.49 10.83 32 40383 8687 32464424
Acute coronary syndrome 13.42 10.83 43 40372 13898 32459213
Myocardial infarction 13.37 10.83 225 40190 125451 32347660
Actinic keratosis 13.16 10.83 20 40395 3890 32469221
Injection site pain 13.14 10.83 13 40402 33045 32440066
Extrasystoles 13.05 10.83 20 40395 3917 32469194
Malignant melanoma stage I 13.05 10.83 5 40410 107 32473004
Dyspnoea exertional 13.01 10.83 88 40327 38873 32434238
Atrial flutter 12.98 10.83 45 40370 15138 32457973
Thyroiditis 12.80 10.83 14 40401 1966 32471145
Angioedema 12.74 10.83 83 40332 36206 32436905
Hypergastrinaemia 12.64 10.83 4 40411 47 32473064
Gastrointestinal tract mucosal pigmentation 12.59 10.83 7 40408 359 32472752
Hypoxia 12.50 10.83 29 40386 52103 32421008
Orthostatic hypotension 12.49 10.83 64 40351 25586 32447525
Ventricular hypokinesia 12.35 10.83 22 40393 4878 32468233
Hypertensive crisis 12.20 10.83 31 40384 8786 32464325
Haemoglobin increased 12.17 10.83 17 40398 3065 32470046
Product use issue 12.15 10.83 30 40385 52747 32420364
Chronic kidney disease 12.00 10.83 88 40327 39887 32433224
Spinal epidural haemorrhage 11.88 10.83 4 40411 58 32473053
Obstruction 11.85 10.83 13 40402 1832 32471279
Blood bicarbonate decreased 11.80 10.83 15 40400 2469 32470642
Psychotic disorder 11.76 10.83 7 40408 23013 32450098
Accidental death 11.72 10.83 14 40401 2163 32470948
Medication error 11.52 10.83 57 40358 22478 32450633
Coronary artery disease 11.45 10.83 103 40312 49603 32423508
Inappropriate antidiuretic hormone secretion 11.42 10.83 37 40378 12026 32461085
Concomitant disease progression 11.36 10.83 15 40400 2563 32470548
Cytomegalovirus infection 11.34 10.83 9 40406 25455 32447656
Foreign body in respiratory tract 11.29 10.83 5 40410 156 32472955
Pancreatic carcinoma metastatic 11.16 10.83 17 40398 3312 32469799
Post thrombotic syndrome 11.15 10.83 5 40410 161 32472950
Skin cancer 11.10 10.83 30 40385 8820 32464291
Tubulointerstitial nephritis 11.08 10.83 51 40364 19526 32453585
Leukopenia 11.05 10.83 38 40377 60084 32413027
Transient ischaemic attack 10.96 10.83 62 40353 25732 32447379
Scan myocardial perfusion abnormal 10.88 10.83 4 40411 76 32473035

Pharmacologic Action:

SourceCodeDescription
ATC C09CA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
ATC C09DB05 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC C09DX07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:61016 angiotensin receptor antagonists
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Diabetic renal disease indication 127013003
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Disorder of muscle contraindication 129565002 DOID:423
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Rhabdomyolysis contraindication 240131006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Azotemia contraindication 445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.37 acidic
pKa2 3.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST Ki 9.10 CHEMBL CHEMBL
Endothelin-1 receptor GPCR Ki 5 CHEMBL
Sodium/bile acid cotransporter Transporter INHIBITOR Ki 4.92 IUPHAR
Type-1B angiotensin II receptor GPCR Ki 9.10 CHEMBL
Angiotensin II receptor (AT-1) type-1 GPCR IC50 8.89 CHEMBL
Angiotensin II receptor GPCR IC50 8.89 CHEMBL

External reference:

IDSource
4021071 VUID
N0000148533 NUI
D00523 KEGG_DRUG
329055-23-4 SECONDARY_CAS_RN
4021071 VANDF
C0288171 UMLSCUI
CHEBI:5959 CHEBI
CHEMBL1513 ChEMBL_ID
D000077405 MESH_DESCRIPTOR_UI
DB01029 DRUGBANK_ID
3749 PUBCHEM_CID
589 IUPHAR_LIGAND_ID
7229 INN_ID
J0E2756Z7N UNII
83818 RXNORM
4917 MMSL
52343 MMSL
d04222 MMSL
006921 NDDF
108585000 SNOMEDCT_US
386877005 SNOMEDCT_US
734504000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5850 TABLET, FILM COATED 75 mg ORAL NDA 29 sections
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5851 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5852 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Avalide HUMAN PRESCRIPTION DRUG LABEL 2 0024-5855 TABLET, FILM COATED 150 mg ORAL NDA 30 sections
Avalide HUMAN PRESCRIPTION DRUG LABEL 2 0024-5856 TABLET, FILM COATED 300 mg ORAL NDA 30 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0054-0254 TABLET 150 mg ORAL ANDA 28 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0054-0255 TABLET 300 mg ORAL ANDA 28 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0093-8232 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0093-8238 TABLET, FILM COATED 150 mg ORAL ANDA 28 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1040 TABLET, FILM COATED 75 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1041 TABLET, FILM COATED 150 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1042 TABLET, FILM COATED 300 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0955-1045 TABLET, FILM COATED 150 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0955-1046 TABLET, FILM COATED 300 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-212 TABLET 75 mg ORAL ANDA 23 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-213 TABLET 150 mg ORAL ANDA 23 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-214 TABLET 300 mg ORAL ANDA 23 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 29300-215 TABLET, FILM COATED 150 mg ORAL ANDA 26 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 29300-216 TABLET, FILM COATED 300 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 31722-160 TABLET 75 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-161 TABLET 150 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-162 TABLET 300 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-729 TABLET 75 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-730 TABLET 150 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-731 TABLET 300 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 33342-047 TABLET 75 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 33342-048 TABLET 150 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 33342-049 TABLET 300 mg ORAL ANDA 26 sections
Irbesartan and Hydrochlorothiazide Human Prescription Drug Label 2 33342-057 TABLET, FILM COATED 150 mg ORAL ANDA 23 sections
Irbesartan and Hydrochlorothiazide Human Prescription Drug Label 2 33342-058 TABLET, FILM COATED 300 mg ORAL ANDA 23 sections